Opportunity
Simpler Grants.gov #FOR-FD-25-015
FDA Cooperative Agreement for Research on Cardiotoxicity of Oncology Therapeutics
Buyer
Food and Drug Administration
Posted
November 20, 2024
Identifier
FOR-FD-25-015
NAICS
541715, 541714
This opportunity invites research organizations to partner with the Food and Drug Administration (FDA) on cardiotoxicity related to oncology therapeutics. - Government Buyer: - Food and Drug Administration (FDA) - OEMs and Vendors: - No specific OEMs or vendors are named, as this is a research grant rather than a product procurement - Products/Services Requested: - Applied regulatory science research focused on evaluating and treating cardiotoxicity caused by oncology therapeutics - Key research areas include: - Standardizing definitions of cardiotoxicity - Use of biomarkers and imaging for detection and monitoring - Functional measures and monitoring plans - Risk stratification and use of electronic health records - Patient-reported outcomes, collaborative networks, and public databases - Innovative treatment approaches and studies on the natural history of cardiotoxicities - Unique or Notable Requirements: - FDA staff will participate in study design and review of interim deliverables - Research must inform regulatory decision making and have practical application - Broad eligibility: government, business, nonprofit, and educational organizations may apply
Description
This funding opportunity supports applied regulatory science research aimed at evaluating and treating cardiotoxicity caused by oncology therapeutics. The research should focus on improving detection, monitoring, and treatment of cardiotoxicity, with outcomes including publications and presentations. The FDA anticipates active involvement in study design and interim deliverables to ensure practical approaches that inform regulatory decision making. Specific areas of interest include standardizing definitions, biomarkers, imaging, functional measures, monitoring plans, risk stratification, use of electronic health records, patient-reported outcomes, collaborative networks, public databases, treatment innovations, and natural history studies.